Drug intelligence / Profile preview

RVM-V002

Development stage: Phase 2
Lead developer: RVAC Medicines
Modality: Small Molecules, mRNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics, Vaccines & Immunotherapeutics
Administration: Intramuscular

Overview

RVM-V002 is a monovalent mRNA vaccine developed by RVAC Medicines for the prevention of COVID-19 infection. It specifically targets the SARS-CoV-2 Omicron variant BA.1. The vaccine works as an immunostimulant by encoding viral antigens that stimulate an immune response against SARS-CoV-2. Clinical development included Phase I/II trials to evaluate its safety, tolerability, and immunogenicity in healthy adults and elderly individuals; however, these trials were terminated due to changes in the COVID-19 pandemic landscape[1][2][5]. The vaccine was intended for use as both a primary and booster vaccination.

Targets

SARS-CoV-2 spike

Beyond the preview

Go deeper on RVM-V002.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on RVM-V002.

Explore the full profile